Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions

Human Gene Therapy

Volumn 13, Issue 1, 2002, Pages 65-100

  Crystal, Ronald G ^a   Harvey, Ben Gary ^a   Wisnivesky, Juan P ^a   O’Donoghue, Kelley A ^a   Chu, Karen W ^b   Maroni, Jaman ^a   Muscat, Jolene C ^a   Pippo, Allison L ^a   Wright, Connie E ^a   Kaner, Robert J ^a   Leopold, Philip L ^a   Kessler, Paul D ^b   Rasmussen, Henrik S ^b   Rosengart, Todd K ^c   Hollmann, Charleen ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b GENVEC INC   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; RECOMBINANT DNA; TRANSMEMBRANE CONDUCTANCE REGULATOR; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ADULT; AGE; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; COLON CARCINOMA; COMORBIDITY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; GENE TRANSFER; HEART SURGERY; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TRANSGENE;

ADENOVIRUSES, HUMAN; ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOSINE DEAMINASE; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; NUCLEOSIDE DEAMINASES; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ADENOVIRIDAE;

EID: 0036147182     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152712647     Document Type: Article

References (57)

1. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy
2. Human gene therapy
3. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors
4. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
5. Study of adenoviral vector-mediated gene transfer in liver in adults with partial ornithine transcarbamylase deficiency (IND 6624): Review of data
6. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA
7. Direct intracerebral nerve growth factor gene transfer using a combinant adenovirus: Effect on basal forebrain cholinergic neurons during aging
8. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
9. Intravenous administration of recombinant adenoviruses causes thrombocytopenia anemia and erythroblastosis in rabbits
10. Transfer of genes to humans: Early lessons and obstacles to success
11. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
12. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung
13. Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis
14. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine
15. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a
16. Structure and genetic organization of adenovirus vectors; adenovirus vectors; strategies to adapt adenoviral vectors for gene therapy applications: Targeting and integration
17. The origins, evolution, and directions of human gene therapy
18. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: A preclinical toxicology study
19. Biodistribution of adenovirus gene therapy vectors in pigs following myocardial administration by various routes
20. Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression
21. Cellular immune responses of healthy individuals to intradermal administration of an E1E3adenovirus gene transfer vector
22. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs
23. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
24. Administration of an E1E3adenovirus vector to airway epithelial cells of normal individuals elicits minimal local host responses
25. Persistence of the vector genome in bronchial epithelial cells of normal individuals following airway spray administration of an E1E3adenovirus vector
26. Safety of local delivery of low and intermediate dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions
27. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector
28. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants
29. Characterization of factors involved in modulating
30. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer
31. Progressive intermittent claudication is associated with impaired fibrinolysis
32. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity
33. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype
34. Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
35. IL-6 release and airway administration of human CFTR cDNA adenovirus vector
36. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
37. Patient recovery after infrainguinal bypass grafting for limb salvage
38. Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: Safety of readministration
39. Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton rat) and non-permissive (mouse) species
40. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121
41. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation
42. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA
43. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
44. Hypothesis testing: Present-time data
45. Regression and correlation methods
46. Use of the logistic model in retrospective studies
47. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: Toxicity study
48. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease
49. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study
50. Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates
51. Adenoviruses as gene-delivery vehicles
52. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
53. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
54. Up-regulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo